{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:46:30Z","timestamp":1791744390520,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB206004"],"award-info":[{"award-number":["20232BAB206004"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03309-0","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T14:47:03Z","timestamp":1779547623000},"page":"1930-1943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary embolism associated with CRBN-targeting immunomodulatory drugs: a FAERS-based pharmacovigilance and mechanistic analysis"],"prefix":"10.1007","volume":"59","author":[{"given":"Bingda","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingbin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"4","key":"3309_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","volume":"20","author":"PL Lutsey","year":"2023","unstructured":"Lutsey PL, Zakai NA (2023) Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol 20(4):248\u2013262. https:\/\/doi.org\/10.1038\/s41569-022-00787-6","journal-title":"Nat Rev Cardiol"},{"key":"3309_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.12.035","author":"S Wolf","year":"2026","unstructured":"Wolf S, Ter Haar SNM, Kenny C et al (2026) Long-term course and recovery following pulmonary embolism. J Thromb Haemost. https:\/\/doi.org\/10.1016\/j.jtha.2025.12.035","journal-title":"J Thromb Haemost"},{"key":"3309_CR3","doi-asserted-by":"publisher","first-page":"115588","DOI":"10.1016\/j.biopha.2023.115588","volume":"170","author":"C Meng","year":"2024","unstructured":"Meng C, Wang X, Fan L et al (2024) A new perspective in the prevention and treatment of antitumor therapy-related cardiotoxicity: Intestinal microecology. Biomed Pharmacother 170:115588. https:\/\/doi.org\/10.1016\/j.biopha.2023.115588","journal-title":"Biomed Pharmacother"},{"key":"3309_CR4","doi-asserted-by":"publisher","first-page":"1601859405","DOI":"10.1177\/20420986251407181","volume":"17","author":"I Kim","year":"2026","unstructured":"Kim I, Makwana A, Ezenma V et al (2026) Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study. Ther Adv Drug Saf 17:1601859405. https:\/\/doi.org\/10.1177\/20420986251407181","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"3309_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00277-026-06811-w","volume":"105","author":"H Ludwig","year":"2026","unstructured":"Ludwig H, Terpos E, Boccadoro M et al (2026) Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma. Ann Hematol 105(1):26. https:\/\/doi.org\/10.1007\/s00277-026-06811-w","journal-title":"Ann Hematol"},{"issue":"3","key":"3309_CR6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s11239-021-02407-5","volume":"52","author":"C Bravo-Perez","year":"2021","unstructured":"Bravo-Perez C, Fern\u00e1ndez-Caballero M, Soler-Espejo E et al (2021) Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma. J Thromb Thrombolysis 52(3):848\u2013853. https:\/\/doi.org\/10.1007\/s11239-021-02407-5","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"3309_CR7","doi-asserted-by":"publisher","first-page":"e70054","DOI":"10.1111\/crj.70054","volume":"19","author":"H Chen","year":"2025","unstructured":"Chen H, Shen Y, Mu Y et al (2025) An exploratory research to evaluate the 30 most common pulmonary embolism drugs in the food and drug administration adverse event reporting system. Clin Respir J 19(6):e70054. https:\/\/doi.org\/10.1111\/crj.70054","journal-title":"Clin Respir J"},{"issue":"2","key":"3309_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ et al (2021) Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract 9(2):819\u2013829. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"3309_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3309_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"3309_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3309_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12916-025-03913-6","volume":"23","author":"W Gao","year":"2025","unstructured":"Gao W, Yu J, Sun Y et al (2025) Adverse events in the nervous system associated with blinatumomab: a real-world study. BMC Med 23(1):72. https:\/\/doi.org\/10.1186\/s12916-025-03913-6","journal-title":"BMC Med"},{"issue":"11","key":"3309_CR13","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1097\/JS9.0000000000002931","volume":"111","author":"X Cai","year":"2025","unstructured":"Cai X, Chen G, Wang H et al (2025) Pharmacovigilance insights into drug-associated venous thromboembolism. Int J Surg 111(11):7677\u20137685. https:\/\/doi.org\/10.1097\/JS9.0000000000002931","journal-title":"Int J Surg"},{"key":"3309_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-026-05024-2","author":"Y Liu","year":"2026","unstructured":"Liu Y, Zhou J, Song L et al (2026) Drug-associated deep vein thrombosis: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-026-05024-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"11","key":"3309_CR15","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ajh.25603","volume":"94","author":"KM Sanfilippo","year":"2019","unstructured":"Sanfilippo KM, Luo S, Wang T et al (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 94(11):1176\u20131184. https:\/\/doi.org\/10.1002\/ajh.25603","journal-title":"Am J Hematol"},{"issue":"2","key":"3309_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/bjh.18630","volume":"201","author":"D Dima","year":"2023","unstructured":"Dima D, Li A, Granat LM et al (2023) External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol 201(2):280\u2013284. https:\/\/doi.org\/10.1111\/bjh.18630","journal-title":"Br J Haematol"},{"key":"3309_CR17","doi-asserted-by":"publisher","first-page":"989032DOI","DOI":"10.3389\/fphar.2022.989032","volume":"13","author":"T Jiang","year":"2022","unstructured":"Jiang T, Su H, Li Y et al (2022) Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system. Front Pharmacol 13:989032DOI. https:\/\/doi.org\/10.3389\/fphar.2022.989032","journal-title":"Front Pharmacol"},{"issue":"2","key":"3309_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","volume":"77","author":"L Lu","year":"2009","unstructured":"Lu L, Payvandi F, Wu L et al (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77(2):78\u201386. https:\/\/doi.org\/10.1016\/j.mvr.2008.08.003","journal-title":"Microvasc Res"},{"issue":"11","key":"3309_CR19","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1021\/acschembio.2c00706","volume":"17","author":"Z Lin","year":"2022","unstructured":"Lin Z, Shen D, Yang B et al (2022) Molecular and structural characterization of lenalidomide-mediated sequestration of eIF3i. ACS Chem Biol 17(11):3229\u20133237. https:\/\/doi.org\/10.1021\/acschembio.2c00706","journal-title":"ACS Chem Biol"},{"key":"3309_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814097","author":"P Li","year":"2023","unstructured":"Li P, Xu B, Xu J et al (2023) Lenalidomide promotes thrombosis formation, but does not affect platelet activation in multiple myeloma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241814097","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3309_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/apha.12725","volume":"219","author":"DA Chistiakov","year":"2017","unstructured":"Chistiakov DA, Orekhov AN, Bobryshev YV (2017) Effects of shear stress on endothelial cells: go with the flow. Acta Physiol (Oxf) 219(2):382\u2013408. https:\/\/doi.org\/10.1111\/apha.12725","journal-title":"Acta Physiol (Oxf)"},{"issue":"3","key":"3309_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1172\/JCI83083","volume":"126","author":"N Baeyens","year":"2016","unstructured":"Baeyens N, Bandyopadhyay C, Coon BG et al (2016) Endothelial fluid shear stress sensing in vascular health and disease. J Clin Invest 126(3):821\u2013828. https:\/\/doi.org\/10.1172\/JCI83083","journal-title":"J Clin Invest"},{"issue":"10","key":"3309_CR23","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1016\/j.jtha.2025.06.012","volume":"23","author":"E Chalayer","year":"2025","unstructured":"Chalayer E, Frere C, Daguenet E et al (2025) Thromboembolism in transplant-ineligible multiple myeloma patients on triplet\/quadruplet therapy: a post hoc analysis of BENEFIT trial. J Thromb Haemost 23(10):3220\u20133230. https:\/\/doi.org\/10.1016\/j.jtha.2025.06.012","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3309_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/bjh.17772","volume":"196","author":"K Piedra","year":"2022","unstructured":"Piedra K, Peterson T, Tan C et al (2022) Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol 196(1):105\u2013109. https:\/\/doi.org\/10.1111\/bjh.17772","journal-title":"Br J Haematol"},{"issue":"8","key":"3309_CR25","doi-asserted-by":"publisher","first-page":"e70177","DOI":"10.1002\/hem3.70177","volume":"9","author":"G Gerotziafas","year":"2025","unstructured":"Gerotziafas G, Fotiou D, Nijhof I et al (2025) Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network. Hemasphere 9(8):e70177. https:\/\/doi.org\/10.1002\/hem3.70177","journal-title":"Hemasphere"},{"issue":"3","key":"3309_CR26","doi-asserted-by":"publisher","first-page":"102865","DOI":"10.1016\/j.rpth.2025.102865","volume":"9","author":"C Codreanu","year":"2025","unstructured":"Codreanu C, Elling T, Veeger NJGM et al (2025) A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma. Res Pract Thromb Haemost 9(3):102865. https:\/\/doi.org\/10.1016\/j.rpth.2025.102865","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03309-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03309-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03309-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:36:53Z","timestamp":1791743813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03309-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3309"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03309-0","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and relevant national guidelines, as it used only publicly available, de-identified data.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}